| Browse All

Black Diamond Therapeutics, Inc. (BDTX)

Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
3.06 USD +0.14 (4.795%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 3.09 +0.03 (0.830%) ⇧ (April 17, 2026, 7:47 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:22 p.m. EDT

BDTX is currently in a volatile state with mixed signals from both the fundamentals and options market. While the company has some positive news and analyst recommendations, the stock has been trading below its 52-week low and shows weak momentum. The lack of dividend history and the negative forward PE suggest caution for long-term investors. Short-term traders might consider buying calls if the stock breaks above the 52-week high, but the options activity suggests a cautious approach. Overall, the stock is not a strong buy at this time.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.105675
AutoTheta0.109949
AutoETS0.111932
AutoARIMA0.113052

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 68%
H-stat 1.41
Ljung-Box p 0.000
Jarque-Bera p 0.337
Excess Kurtosis -0.57
Attribute Value
Sector Healthcare
Debt to Equity Ratio 16.737
Revenue per Share 1.231
Market Cap 175,303,584
Trailing P/E 7.85
Forward P/E -2.97
Beta 3.39
Profit Margins 31.95%
Website https://www.blackdiamondtherapeutics.com

As of April 11, 2026, 1:22 p.m. EDT: Options speculators are showing mixed signals. Calls are heavily weighted towards strikes around $2.50, suggesting a potential bullish bias, while puts are concentrated on lower strikes, indicating some bearish sentiment. The high open interest in out-of-the-money puts suggests a possible fear of further downside, but the presence of significant call volume at the ATM strike indicates some confidence in the stock's stability. The overall options activity suggests a cautious approach with potential for upward movement, but not strong enough to indicate a clear trend.


Info Dump

Attribute Value
52 Week Change 1.0536914
Address1 245 First Street
Address2 18th Floor
All Time High 46.25
All Time Low 1.18
Ask 3.09
Ask Size 8
Average Analyst Rating 1.4 - Strong Buy
Average Daily Volume10 Day 846,530
Average Daily Volume3 Month 702,411
Average Volume 702,411
Average Volume10Days 846,530
Beta 3.39
Bid 3.02
Bid Size 8
Book Value 1.964
City Cambridge
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 3.06
Current Ratio 8.419
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 3.09
Day Low 2.97
Debt To Equity 16.737
Display Name Black Diamond Therapeutics
Earnings Timestamp 1,773,691,200
Earnings Timestamp End 1,778,529,600
Earnings Timestamp Start 1,778,529,600
Ebitda 20,195,000
Ebitda Margins 0.2885
Enterprise To Ebitda 3.24
Enterprise To Revenue 0.935
Enterprise Value 65,432,576
Eps Current Year -0.63857
Eps Forward -1.032
Eps Trailing Twelve Months 0.39
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.3347
Fifty Day Average Change 0.72529984
Fifty Day Average Change Percent 0.3106608
Fifty Two Week Change Percent 105.36914
Fifty Two Week High 4.94
Fifty Two Week High Change -1.8800001
Fifty Two Week High Change Percent -0.3805668
Fifty Two Week Low 1.39
Fifty Two Week Low Change 1.67
Fifty Two Week Low Change Percent 1.2014388
Fifty Two Week Range 1.39 - 4.94
Financial Currency USD
First Trade Date Milliseconds 1,580,481,000,000
Float Shares 46,246,343
Forward Eps -1.032
Forward P E -2.9651163
Free Cashflow 13,033,750
Full Exchange Name NasdaqGS
Full Time Employees 21
Gmt Off Set Milliseconds -14,400,000
Gross Margins 1.0
Gross Profits 70,000,000
Has Pre Post Market Data 1
Held Percent Insiders 0.00622
Held Percent Institutions 0.77575
Implied Shares Outstanding 57,288,750
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Long Name Black Diamond Therapeutics, Inc.
Market us_market
Market Cap 175,303,584
Market State CLOSED
Max Age 86,400
Message Board Id finmb_424913244
Most Recent Quarter 1,767,139,200
Net Income To Common 22,367,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 175,590,018
Number Of Analyst Opinions 7
Open 2.98
Operating Cashflow 29,614,000
Operating Margins 0.28386
Payout Ratio 0.0
Phone 617 252 0848
Post Market Change 0.025400162
Post Market Change Percent 0.8300707
Post Market Price 3.0854
Post Market Time 1,776,469,631
Previous Close 2.92
Price Eps Current Year -4.791957
Price Hint 4
Price To Book 1.5580448
Price To Sales Trailing12 Months 2.5043368
Profit Margins 0.31952998
Quick Ratio 8.178
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.44444
Region US
Regular Market Change 0.14
Regular Market Change Percent 4.79452
Regular Market Day High 3.09
Regular Market Day Low 2.97
Regular Market Day Range 2.97 - 3.09
Regular Market Open 2.98
Regular Market Previous Close 2.92
Regular Market Price 3.06
Regular Market Time 1,776,456,001
Regular Market Volume 998,094
Return On Assets 0.0935
Return On Equity 0.22882
Revenue Per Share 1.231
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 57,288,750
Shares Percent Shares Out 0.0885
Shares Short 5,067,871
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 4,625,166
Short Name Black Diamond Therapeutics, Inc
Short Percent Of Float 0.1267
Short Ratio 8.13
Source Interval 15
State MA
Symbol BDTX
Target High Price 14.0
Target Low Price 7.0
Target Mean Price 9.71429
Target Median Price 10.0
Total Cash 128,652,000
Total Cash Per Share 2.246
Total Debt 18,781,000
Total Revenue 70,000,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.39
Trailing P E 7.846154
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.939975
Two Hundred Day Average Change 0.12002492
Two Hundred Day Average Change Percent 0.04082515
Type Disp Equity
Volume 998,094
Website https://www.blackdiamondtherapeutics.com
Zip 2,142